Rachel M. Belcher

Rachel M. Belcher

Auto-generated profile, based on publicly available information

Rachel M. Belcher

Department of Pharmacy Practice University of Illinois Chicago College of Pharmacy Denver Colorado USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2022 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
JKJason H. Karnes
Jason H. Karnes
TATomefa Asempa
Tomefa Asempa
JBJason N. Barreto
Jason N. Barreto
RBRachel M. Belcher
Rachel M. Belcher
BBBrittany D. Bissell
Brittany D. Bissell
P. Brandon BookstaverP. Brandon Bookstaver
P. Brandon Bookstaver

18 July 2024 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
RBRachel M. Belcher
Rachel M. Belcher
BSBenjamin Shultz
Benjamin Shultz
JMJeffrey Mucksavage
Jeffrey Mucksavage
EHEverton Herrera
Everton Herrera
SBScott Thomas Benken
Scott Thomas Benken

21 August 2024 in Clinical Transplantation
Verified
Journal Article
Open access
LBLyra P. Beltran
Lyra P. Beltran
JBJamie Benken
Jamie Benken
JJJonathan Jou
Jonathan Jou
EBEnrico Benedetti
Enrico Benedetti
HNHokuto Nishioka
Hokuto Nishioka
SBScott Thomas Benken
Scott Thomas Benken
Introduction: Angiotensin II (ATII) maintains blood pressure via RAAS with a beneficial adverse effect profile versus catecholamines and phenylephrine. Head‐to‐head data comparing ATII to phenylephrine are lacking regarding renal allograft function, hemodynamic efficacy, and safety within the perioperative period of kidney transplantation.Methods: This single‐center, retrospective study included adult kidney transplant recipients who received continuous infusions of ATII or phenylephrine within a 24‐h perioperative period as a first‐line vasopressor according to an institutional algorithm. The primary endpoint was allograft function. Secondary endpoints were hemodynamic efficacy and adverse effects.Results: Among 105 patients, there was no significant difference in IGF (p = 0.545), SGF (p = 0.557), or DGF (p = 0.878) between patient cohorts. In the 34 patients with cold ischemia time (CIT) > 14‐h, IGF was higher (p = 0.013) and DGF (p = 0.045) was lower in the ATII cohort versus phenylephrine. In all patients, ATII was associated with a decreased need for additional vasopressor agents (p < 0.001). Adverse effect profiles were similar between cohorts (p > 0.05).Conclusion: Among kidney transplant recipients, ATII may be a suitable first‐line alternative compared with phenylephrine in the perioperative period for hypotension management with a reduced need for additional vasopressor support. Allograft benefits were observed in patients with prolonged CIT.

5 July 2023 in Transplantation Proceedings
Verified
Journal Article
Closed access
RTRiya Thomas
Riya Thomas
JBJamie Benken
Jamie Benken
RBRachel M. Belcher
Rachel M. Belcher
MPMary E. Palmer
Mary E. Palmer
EBEnrico Benedetti
Enrico Benedetti
SBScott Thomas Benken
Scott Thomas Benken

11 July 2023 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MPMary E. Palmer
Mary E. Palmer
RBRachel M. Belcher
Rachel M. Belcher
AEAnastasia Engeleit
Anastasia Engeleit
EWEric Wenzler
Eric Wenzler
ZBZackery Bulman
Zackery Bulman
SBScott Thomas Benken
Scott Thomas Benken